GlassScriptPhysician profile
Xue Gao
NPI 1598381535
$2,746.95
in general payments reported to CMS, 2019-2025
12 companies · $499 in 2025
The $499 reported for 2025 was more than what 75% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $592 · 2023: $743 · 2024: $497 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $751.86 | 2022-2025 | Epclusa, Vemlidy, Livdelzi |
| Abbvie INC. | $593.08 | 2021-2024 | |
| Celgene Corporation | $560.47 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $250.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $130.66 | 2024-2025 | Zenpep, Vowst |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Airsupra |
| Celltrion USA INC. | $107.64 | 2024-2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.07 | 2021-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $65.31 | 2022-2023 | |
| Redhill Biopharma INC. | $39.25 | 2022 | |
| Amarin Pharma, INC. | $19.98 | 2021 | |
| Braintree Laboratories, INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xue Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.